Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2023

Sep 6, 2023

31100_dirs_2023-09-06_9aa94117-06b4-46f9-9ace-841bb840db31.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-09-05

Reporting Person: Cowan Elvia (SVP, Finance)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-09-05 Common Stock F 627 $51.00 Disposed 7301 Direct

Footnotes

F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F2: Includes 678 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023.